Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 833

1.

Infant serotonin transporter (SLC6A4) promoter genotype is associated with adverse neonatal outcomes after prenatal exposure to serotonin reuptake inhibitor medications.

Oberlander TF, Bonaguro RJ, Misri S, Papsdorf M, Ross CJ, Simpson EM.

Mol Psychiatry. 2008 Jan;13(1):65-73. Epub 2007 May 22.

PMID:
17519929
2.

Prenatal effects of selective serotonin reuptake inhibitor antidepressants, serotonin transporter promoter genotype (SLC6A4), and maternal mood on child behavior at 3 years of age.

Oberlander TF, Papsdorf M, Brain UM, Misri S, Ross C, Grunau RE.

Arch Pediatr Adolesc Med. 2010 May;164(5):444-51. doi: 10.1001/archpediatrics.2010.51.

PMID:
20439795
3.

Neonatal S100B protein levels after prenatal exposure to selective serotonin reuptake inhibitors.

Pawluski JL, Galea LA, Brain U, Papsdorf M, Oberlander TF.

Pediatrics. 2009 Oct;124(4):e662-70. doi: 10.1542/peds.2009-0442. Epub 2009 Sep 28.

PMID:
19786426
4.

Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data.

Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C.

Arch Gen Psychiatry. 2006 Aug;63(8):898-906.

PMID:
16894066
5.

Effects of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: population-based study.

Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C.

Br J Psychiatry. 2008 May;192(5):338-43. doi: 10.1192/bjp.bp.107.037101.

6.

Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure.

Oberlander TF, Misri S, Fitzgerald CE, Kostaras X, Rurak D, Riggs W.

J Clin Psychiatry. 2004 Feb;65(2):230-7.

PMID:
15003078
7.

Neonatal growth outcomes at birth and one month postpartum following in utero exposure to antidepressant medication.

Lewis AJ, Galbally M, Opie G, Buist A.

Aust N Z J Psychiatry. 2010 May;44(5):482-7. doi: 10.3109/00048670903559593.

PMID:
20397792
8.

Antidepressant use during pregnancy and serotonin transporter genotype (SLC6A4) affect newborn serum reelin levels.

Brummelte S, Galea LA, Devlin AM, Oberlander TF.

Dev Psychobiol. 2013 Jul;55(5):518-29. doi: 10.1002/dev.21056. Epub 2012 Jun 12.

PMID:
22692766
9.

Pain reactivity in 2-month-old infants after prenatal and postnatal serotonin reuptake inhibitor medication exposure.

Oberlander TF, Grunau RE, Fitzgerald C, Papsdorf M, Rurak D, Riggs W.

Pediatrics. 2005 Feb;115(2):411-25.

PMID:
15687451
10.

Neonate characteristics after maternal use of antidepressants in late pregnancy.

Källén B.

Arch Pediatr Adolesc Med. 2004 Apr;158(4):312-6.

PMID:
15066868
11.

Obstetrical and neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitors: the relevance of dose.

Roca A, Garcia-Esteve L, Imaz ML, Torres A, Hernández S, Botet F, Gelabert E, Subirà S, Plaza A, Valdés M, Martin-Santos R.

J Affect Disord. 2011 Dec;135(1-3):208-15. doi: 10.1016/j.jad.2011.07.022. Epub 2011 Sep 3.

PMID:
21890210
12.

Neonatal outcome following pregnancy exposure to antidepressants: a prospective controlled cohort study.

Maschi S, Clavenna A, Campi R, Schiavetti B, Bernat M, Bonati M.

BJOG. 2008 Jan;115(2):283-9. Epub 2007 Sep 27.

13.

Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes.

Lund N, Pedersen LH, Henriksen TB.

Arch Pediatr Adolesc Med. 2009 Oct;163(10):949-54. doi: 10.1001/archpediatrics.2009.164. Erratum in: Arch Pediatr Adolesc Med. 2009 Dec;163(12):1143.

PMID:
19805715
14.

Externalizing and attentional behaviors in children of depressed mothers treated with a selective serotonin reuptake inhibitor antidepressant during pregnancy.

Oberlander TF, Reebye P, Misri S, Papsdorf M, Kim J, Grunau RE.

Arch Pediatr Adolesc Med. 2007 Jan;161(1):22-9.

PMID:
17199063
15.

Birth outcomes following prenatal exposure to antidepressants.

Pearson KH, Nonacs RM, Viguera AC, Heller VL, Petrillo LF, Brandes M, Hennen J, Cohen LS.

J Clin Psychiatry. 2007 Aug;68(8):1284-9.

PMID:
17854255
16.

A new look at the neonate's clinical presentation after in utero exposure to antidepressants in late pregnancy.

Boucher N, Bairam A, Beaulac-Baillargeon L.

J Clin Psychopharmacol. 2008 Jun;28(3):334-9. doi: 10.1097/JCP.0b013e318173aa2e.

PMID:
18480693
17.

Prenatal serotonin reuptake inhibitor (SRI) antidepressant exposure and serotonin transporter promoter genotype (SLC6A4) influence executive functions at 6 years of age.

Weikum WM, Brain U, Chau CM, Grunau RE, Boyce WT, Diamond A, Oberlander TF.

Front Cell Neurosci. 2013 Oct 11;7:180. doi: 10.3389/fncel.2013.00180. eCollection 2013.

18.

Length of prenatal exposure to selective serotonin reuptake inhibitor (SSRI) antidepressants: effects on neonatal adaptation and psychomotor development.

Casper RC, Gilles AA, Fleisher BE, Baran J, Enns G, Lazzeroni LC.

Psychopharmacology (Berl). 2011 Sep;217(2):211-9. doi: 10.1007/s00213-011-2270-z. Epub 2011 Apr 16.

PMID:
21499702
19.

Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications.

Moses-Kolko EL, Bogen D, Perel J, Bregar A, Uhl K, Levin B, Wisner KL.

JAMA. 2005 May 18;293(19):2372-83. Review.

PMID:
15900008
20.

Serotonin reuptake inhibitor use in pregnancy and the neonatal behavioral syndrome.

Jordan AE, Jackson GL, Deardorff D, Shivakumar G, McIntire DD, Dashe JS.

J Matern Fetal Neonatal Med. 2008 Oct;21(10):745-51. doi: 10.1080/14767050802255488.

PMID:
19012191
Items per page

Supplemental Content

Write to the Help Desk